Cardiovascular vs Infectious Disease — Deal Terms Comparison

Cardiovascular Median Upfront

$606M

Total: $3.0B

Infectious Disease Median Upfront

$604M

Total: $2.3B

Cardiovascular Royalties

9.4%-18.7%

Tiered to 22.7%

Infectious Disease Royalties

8.1%-16.3%

Tiered to 20.3%

Model Your Deal

Market Analysis

Cardiovascular and Infectious Disease represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 cardiovascular deals carry a median total deal value of $3.0B with $606M upfront, compared to $2.3B total value and $604M upfront for infectious disease. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

Deal structures differ across therapeutic areas. Cardiovascular deals allocate 20% to upfront and 80% to milestones, while Infectious Disease deals split 26%/74%. Development milestones are $537M for cardiovascular versus $376M for infectious disease, reflecting the different clinical trial designs and approval standards in each area.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do cardiovascular and infectious disease deal terms compare?

Cardiovascular Phase 2 deals average $3.0B total value ($606M upfront), while Infectious Disease deals average $2.3B ($604M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.

Which therapeutic area commands higher royalty rates: Cardiovascular or Infectious Disease?

Cardiovascular base royalties range from 9.4% to 18.7%, while Infectious Disease royalties range from 8.1% to 16.3%. Royalty rates reflect pricing power, competitive dynamics, and patent protection characteristics specific to each therapeutic area.

What drives the deal value differences between cardiovascular and infectious disease?

Key factors include addressable patient population size, clinical trial costs and timelines, regulatory pathway complexity, pricing and reimbursement dynamics, and competitive landscape density. Cardiovascular and Infectious Disease each have unique value drivers that shape deal economics.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included